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EEXPAND (phase Ib, dose-finding study) evaluated the starting doseof ruxolitinib in patients with myelofibrosis with baseline plateletcounts of 50-99×109/L. The study consisted of dose-escalation and
safety-expansion phases. Based on the baseline platelet counts, patients
were assigned to stratum 1 (75-99x109/L) or stratum 2 (50-74x109/L),
with the primary objective of determining the maximum safe starting
dose (MSSD); key secondary objectives included safety and efficacy. At
week 48 data cutoff (stratum 1, n=44; stratum 2, n=25), 24.6% (17 out of
69) of patients were still receiving treatment. The MSSD was established
as ruxolitinib 10 mg twice daily in both strata. Thrombocytopenia [grade
4 (stratum 1, n=1; stratum 2, n=2)] was the only reported dose-limiting
toxicity (study drug related) at 10 mg twice daily. In the MSSD cohort
(stratum 1, n=20; stratum 2, n=18), adverse events (regardless of study
drug relationship) led to treatment discontinuation in 15.0% and 33.3%
of patients in stratum 1 and stratum 2, respectively, and dose adjust-
ment/interruption in 45.0% and 66.7% of patients in stratum 1 and stra-
tum 2, respectively. Three cases of on-treatment deaths were reported at
the MSSD. Spleen response was achieved at week 48 in 33.3% and
30.0% of patients in stratum 1 and stratum 2, respectively.
Improvements in the Total Symptom Score were also observed. In this
study, ruxolitinib demonstrated acceptable tolerability in both the strata
at the MSSD of 10 mg twice daily. (Registered at: clinicaltrials.gov identifier:
01317875).   
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ABSTRACT
Introduction
Myelofibrosis (MF) is a rare, chronic, Philadelphia chromosome-negative myelo-
proliferative neoplasm caused by clonal proliferation of pluripotent hematopoietic
stem cells.1,2 The common clinical presentations associated with MF include
splenomegaly due to extramedullary hematopoiesis, progressive bone marrow
fibrosis with cytopenias, and debilitating constitutional symptoms (e.g., fatigue,
night sweats, and fever), which substantially diminish the quality of life.3-6 The dys-
regulated activation of the Janus kinase (JAK)/signal transducer and activator of tran-
scription pathway is the hallmark of MF and can result from mutations in JAK2, in
the cytokine receptor, or in other components of the signaling pathway.7,8
Ruxolitinib, a potent and selective oral JAK1/JAK2 inhibitor, was approved for the
treatment of intermediate- and high-risk patients with MF based on two random-
ized, phase III studies: COMFORT-I (n=309; clinicaltrials.gov identifier: 00952289) and
COMFORT-II (n=219; clinicaltrials.gov identifier:
00934544).9-12 In both COMFORT studies, ruxolitinib
demonstrated marked and sustained clinical benefits in
spleen size and improvement in symptom burden, and
was generally well tolerated.9-12
Patients with MF may present with thrombocytopenia
(platelet counts, <100x109/L) owing to the nature of the
disease.13,14 Across various studies, approximately 16-26%
of patients with MF were found to be thrombocytopenic
at diagnosis.15-19 In addition, patients with MF may also
experience treatment-emergent thrombocytopenia while
on ruxolitinib therapy (owing to its mechanism of
action).9,12,20 The Study 251 (n=153; clinicaltrials.gov identifi-
er: 00509899) identified thrombocytopenia as a dose-lim-
iting toxicity (DLT) for ruxolitinib.21 Patients in the COM-
FORT studies had baseline platelet counts ≥100x109/L,
limiting the safety and efficacy data in patients with lower
platelet counts.14,18,21 
To date, only a few treatment options have been 
evaluated for patients with MF and thrombocytopenia.
The safety and efficacy of JAK inhibitors in thrombocy-
topenic patients with MF have also not been adequately
explored.15,22 Evidence from clinical trials evaluating the
use of ruxolitinib in patients with MF with baseline
thrombocytopenia (platelet counts <100x109/L) is 
limited.14,23-25
The Study 258 (n=50; clinicaltrials.gov identifier:
01348490) evaluated the efficacy and safety of low-dose
ruxolitinib [5 mg twice daily (bid)] with subsequent dose
escalation in patients with low platelet counts (50 to
<100x109/L).14 Ruxolitinib was generally well tolerated
and provided efficacy benefits, suggesting that a starting
dose of 5 mg bid with escalation to 10 mg bid may be suit-
able for the low platelet count population.14 
The JUMP study (n=2233; 
clinicaltrials.gov.identifier: 01493414), a phase IIIb expanded-
access study, was amended to enroll patients with base-
line platelet counts ≥50x109/L to gather additional safety
and efficacy data in patients with low platelet counts.23-25
In the JUMP study, the safety profile of ruxolitinib in the
low-platelet patient cohort was consistent with that
observed in patients with platelet counts ≥100x109/L.
Spleen and symptom responses achieved with low-dose
ruxolitinib (5 mg bid) were within the expected range
based on the COMFORT studies.23 
The recommended starting dose of ruxolitinib 
(prescribing information) is based on the platelet count.26
The maximum recommended starting dose in patients
with platelet counts between 50x109/L and 100x109/L is 5
mg bid, and the dose should be titrated with caution.26,27
However, the findings from the COMFORT-I and the
Study 258 demonstrated that the final titrated doses of 
≥10 mg bid resulted in larger improvements in spleen vol-
ume and MF-related symptoms compared to titrated
doses of ≤5 mg bid.14,28 
The purpose of the EXPAND study (clinicaltrials.gov iden-
tifier: 01317875: open-label, phase Ib, dose-finding study)
was to establish the maximum safe starting dose (MSSD)
of ruxolitinib in patients with MF with baseline platelet
counts between 50x109/L and 100x109/L. The study also
intended to assess the safety and tolerability of ruxolitinib
in this patient population.
The preliminary findings from the dose-escalation and
safety-expansion phases of EXPAND at the preplanned
interim analysis [day 168 (week 24)] were previously
reported.29 Guided by the occurrence of protocol-defined
DLTs during the first cycle of treatment (28 days), 15 mg
bid was initially declared as the MSSD for patients
enrolled in stratum 1 (S1; platelet counts: 75-99×109/L) of
the study, whereas 10 mg bid was declared as the MSSD
for patients in stratum 2 (S2; platelet counts: 50-74×109/L).
However, based on the safety and efficacy findings from
the interim analysis, the MSSD for S1 was subsequently
lowered to 10 mg bid (as per the protocol amendment).
Here, we present the results from the 48-week follow up
of EXPAND for the MSSD cohorts.
Methods
Patient population
Eligible patients: i) were aged ≥18 years; ii) had been diagnosed
with intermediate-1, intermediate-2, or high-risk MF (primary MF,
post-polycythemia vera MF, or post-essential thrombocythemia
MF);30 iii) had a palpable spleen (≥5 cm from the costal margin);
and iv) fulfilled the platelet count criteria at screening or study day
1 (S1: <100x109/L and ≥75x109/L; S2: <75x109/L and ≥50x109/L).
An Eastern Oncology Cooperative Group performance status of
≤2 was required at screening. The key exclusion 
criteria included: i) patients with any history of platelet counts
<45x109/L within 30 days prior to screening; ii)  platelet transfu-
sion within 14 days prior to screening; iii)  history or predisposi-
tion to clinically significant bleeding; iv)  history of platelet dys-
function and/or bleeding diathesis; and v) regular use of drugs
inhibiting platelet function.
Study design
EXPAND was a phase Ib, open-label, multicenter, dose-finding
study of ruxolitinib in patients with intermediate- or high-risk 
primary MF, post-polycythemia vera MF, or post-essential throm-
bocythemia MF who had baseline platelet counts between
≥50x109/L and <100x109/L. The study design is shown in Figure 1. 
The study period consisted of 2 phases: dose escalation and
safety expansion. The successive cohorts of newly enrolled
patients received increasing doses of ruxolitinib until the MSSD
was determined in the dose-escalation phase. The MSSD was
defined as the dose level most closely associated with a posterior
probability of DLT between 16% and 33% that did not also have
>25% probability of excessive toxicity. A DLT was defined as the
occurrence of any treatment-related toxicity occurring through
study day 28 (Online Supplementary Table S1). A preplanned 
interim analysis was conducted when the last patient enrolled in
the dose-escalation phase completed week 24.29
An adaptive Bayesian logistic regression model guided by 
escalation with overdose control was used to allocate patients into
each cohort (5 dose levels) in the dose-escalation phase (Treatment
Dose Levels) (Online Supplementary Appendix). The patients in the
dose-determining set (DDS) enrolled in the dose-finding part of
the study were assessed to determine the MSSD. The DDS 
consisted of all patients from the safety set who met the minimum
exposure criterion and had sufficient safety evaluations or who
experienced a DLT. The safety set consisted of all patients who
received at least 1 dose of ruxolitinib. The DDS definition, mini-
mum exposure criterion, and planned enrollment are provided in
the Online Supplementary Appendix. 
The safety-expansion phase was conducted after determination
of the MSSD to further evaluate the safety and tolerability of the
MSSD, and establish that the dose was suitable for use in patients
with MF with low platelet counts. Per protocol amendment, 
10 mg bid was evaluated as the starting dose for all new patients
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enrolled in S1 in the safety-expansion phase (Online Supplementary
Appendix). Patients who were already receiving the 15 mg bid dose
continued to take their assigned dose.
The end of the study will occur after all study patients complete
their last assessment as per protocol (follow-up visit 30 days after
the end of the treatment visit) (Online Supplementary Appendix).
Details of the statistical analyses are presented in the Online
Supplementary Appendix.
The study was approved by the institutional review boards of
the respective institutions prior to patient enrollment and was
conducted in accordance with the principles of the Declaration of
Helsinki. All patients provided written informed consent. The trial
is registered at clinicaltrials.gov identifier: 01317875.
Assessments
In the dose-escalation phase, the primary objective was to
determine the MSSD (incidence rate of DLTs) of ruxolitinib. The
key secondary objectives included safety [frequency, duration, and
severity of adverse events (AEs) and serious AEs] and efficacy
(spleen response: proportion of patients achieving ≥50% of reduc-
tion in palpable measurement of spleen length at week 48 data
cutoff relative to day 1). The key exploratory objectives included
patient-reported outcomes [change in the Total Symptom Score
(TSS) as assessed by the modified Myelofibrosis Symptom
Assessment Form (MFSAF) v.2.0 diary].31-33 
Results
Results from the interim analysis (week 24 data cutoff: January
20, 2015) of the study have been presented at the 2015 American
Society of Hematology meeting.29 At that data cutoff, 46 patients
(S1, n=27; S2, n=19) had received treatment. 
Overall study cohort 
At week 48 data cutoff (December 7, 2017), the final enrollment
for EXPAND included 69 patients (S1, n=44; S2, n=25) (Online
Supplementary Table S2). Overall, 31.8% (14 out of 44) of patients
in S1 and 12.0% (3 out of 25) of patients in S2 were still receiving
ruxolitinib treatment (Online Supplementary Table S3). The median
exposure to ruxolitinib was 51.4 weeks (range, 0.9-210.0 weeks) in
S1 and 67.4 weeks (range, 4.4-161.1 weeks) in S2.
The AEs (in ≥20% of patients in either stratum, regardless of
study drug relationship) reported in the overall cohort are 
presented in Online Supplementary Table S4. Reasons for on-treat-
ment death included acute myeloid leukemia (1 patient), cardiac
arrest (1 patient), and unknown (1 patient, not suspected to be
related to study drug) in S1 and complications following gastroin-
testinal ulcer (1 patient) and multiple organ failure (1 patient) in S2
(Online Supplementary Table S5). Hemoglobin levels and platelet
counts over time are presented in Figure 2. An initial decrease in
the blood count parameters was observed in the first few weeks;
however, the parameters stabilized with time. Spleen response at
week 48 was achieved in 7 out of 22 patients [31.8% (95%CI:
13.9, 54.9)] in S1 and 5 out of 14 patients [35.7% (95%CI: 12.8,
64.9)] in S2. A spleen response at any time point was observed in
22 out of 43 patients [51.2% (95%CI: 35.5, 66.7)] in S1 and 17 out
of 25 patients [68.0% (95%CI: 46.5, 85.1)] in S2 (Online
Supplementary Figure S1).
Maximum safe starting dose cohort 
Patients’ characteristics. Baseline patients’ characteristics (S1,
n=20; S2, n=18) were indicative of an advanced disease stage
(Online Supplementary Table S6). In the MSSD cohort, 70.0% (14
out of 20) of patients in S1 and 16.7% (3 out of 18) of patients in
S2 were still receiving ruxolitinib treatment (Table 1). The primary
reasons for the end of treatment included AEs [S1, n=1 (5.0%); S2,
EXPAND: 48-week follow-up analysis
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Figure 1. Study design. Dark arrows represent escalation from a given dose level to the following one, only if both that dose level and the previous one have been
deemed safe. Dotted arrows represent each dose level in stratum 2, which will open to patients only if both that dose level and the following one have been deemed
safe in stratum 1. Per protocol amendment, new patients enrolled in stratum 1 in the safety-expansion phase will be given the 10 mg twice-daily (bid) dose instead
of the 15 mg bid dose level previously evaluated as the maximum safe starting dose (MSSD). The MSSD cohort (10 mg bid) in stratum 1 included 3 patients from
the dose-escalation and 17 patients from the safety-expansion phases. In stratum 2, the MSSD cohort included 8 patients from the dose-escalation and 10 patients
from the safety-expansion phases. 
n=4 (22.2%)], treatment duration completed [S1, n=0; S2, n=3
(16.7%]), physician decision [S1, n=1 (5.0%); S2, n=3 (16.7%)],
disease progression [S1, n=3 (15.0%); S2, n=1 (5.6%)], and death
[S1, n=0; S2, n=2 (11.1%)]. 
Dosing and exposure. The median exposure to ruxolitinib was
54.8 weeks (range, 4.3-210.0 weeks) in S1 and 83.2 weeks (range,
4.4-161.1 weeks) in S2. Overall, 45.0% (9 out of 20) of patients in
S1 and 88.9% (16 out of 18) of patients in S2 had at least 1 dose
reduction/interruption (Online Supplementary Table S7). The mean
total daily dose over time plot by stratum at MSSD (10 mg bid in
both S1 and S2) is shown in Figure 3. The mean dose intensity was
17.96 mg/day [standard deviation (SD)=3.055] in S1 and 
13.27 mg/day (SD=5.030) in S2.
Dose modifications were observed during the first 12 weeks of
treatment in some patients; 30.0% (6 out of 20) of patients in S1
and 61.1% (11 out of 18) of patients in S2 had at least 1 dose
reduction/interruption (Online Supplementary Table S8). Among
these patients with a dose down-titration, 3 of 6 patients in S1 and
10 of 11 patients in S2 did not resume the initial 10 mg bid dose.
Thrombocytopenia was the most frequent AE leading to an early
dose titration.
Safety in the maximum safe starting dose cohort  
Adverse events (in ≥15% of patients in either stratum, regard-
less of study drug relationship) in the MSSD cohort are presented
in Table 2. As observed in the interim analysis, anemia and 
thrombocytopenia (all grades) were the most common hemato-
logic AEs in both strata [anemia: S1, n=9 (45.0%); S2, n=8 (44.4%)
and thrombocytopenia: S1, n=8 (40.0%); S2, n=14 (77.8%)].
Grade 3 or 4 AEs were reported in 70.0% (14 out of 20) of patients
in S1 and 88.9% (16 out of 18) of patients in S2. The AEs [regard-
less of study drug relationship; any system organ class (SOC)] led
to treatment discontinuation in 15.0% (3 out of 20) of patients in
S1 and 33.3% (6 out of 18) of patients in S2, with thrombocytope-
nia being reported as the most common reason for treatment dis-
continuation [S1, n=1 (5.0%); S2, n=3 (16.7%)]. Dose adjustment
or study drug interruption due to AEs [regardless of study drug
relationship (any SOC)] was observed in 45.0% (9 out of 20) of
patients in S1 and 66.7% (12 out of 18) of patients in S2.
Thrombocytopenia was the primary reason for dose
adjustment/interruption in both strata [S1, n=4 (20.0%); S2, n=12
(66.7%)]. Overall, 25% (5 out of 20) of patients in S1 and 38.9%
(7 out of 18) of patients in S2 experienced a serious AE [regardless
of study drug relationship (any SOC)]. Thrombocytopenia (grade
4, related to study drug) was the only DLT reported in both strata
at 10 mg bid [S1, n=1; S2, n=2 (1 DLT in S2 was reported at the
interim analysis)]. Grade 4 worsening from baseline in platelet
count was observed in 1 patient (5.0%) in S1 and 7 patients
(38.9%) in S2 (Table 3). No grade 4 worsening from baseline was
reported in either stratum for hemoglobin levels. Reasons for on-
treatment death (in the MSSD cohort) included acute myeloid
leukemia (1 patient) and cardiac arrest (1 patient) in S1, and multi-
ple organ failure (1 patient) in S2 (Online Supplementary Table S5).
A.M. Vannucchi et al.
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Figure 2. Blood parameters over time. (A) Hemoglobin levels. (B) platelet counts. BL: baseline.
Table 1. Patient disposition (week 48 analysis; maximum safe starting
dose cohort). 
Patient disposition                         Stratum 1 (N=20)     Stratum 2 (N=18)
                                                               N (%)                        N (%)
Patients treated
End of treatment                                         6 (30.0)                       15 (83.3)       
Treatment ongoinga                                    14 (70.0)                       3 (16.7)       
Primary reason for end of treatment
AE                                                                     1 (5.0)                         4 (22.2)       
Completed                                                           0                               3 (16.7)       
Death                                                                     0                               2 (11.1)       
Other                                                               1 (5.0)                                0
Physician decision                                        1 (5.0)                          3 (16.7)       
Progressive disease                                    3 (15.0)                          1 (5.6)       
Withdrawal by patient                                       0                               2 (11.1)       
AE: adverse event. aPatients under ongoing treatment at the time of data cutoff
(December 7, 2017). 
A
B
Efficacy in the maximum safe starting dose cohort
Spleen response. At week 48, spleen response was achieved in 5
out of 15 patients [33.3% (95%CI: 11.8, 61.6)] in S1 and 3 out of
10 patients [30.0% (95%CI: 6.7, 65.2)] in S2. A spleen response at
any time point was observed in 8 out of 20 patients [40.0%
(95%CI: 19.1, 63.9)] in S1 and 12 out of 18 patients [66.7%
(95%CI: 41.0, 86.7)] in S2 (Figure 4).
The waterfall plot for the best response in spleen length for
patients treated at the MSSD, with or without dose titration,
within the first 12 weeks is presented in Online Supplementary
Figure S2. A decrease in best percentage change from baseline in
spleen length was evident in 100.0% of patients with dose down-
EXPAND: 48-week follow-up analysis
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Table 2. All grade adverse events, regardless of study drug relationship, in ≥15% of patients in either stratum (week 48 analysis; maximum safe
starting dose cohort).
Preferred term                                                                        Stratum 1 (N=20)                                                     Stratum 2 (N=18)
                                                                                   All grades                    Grade 3 or 4                        All grades                     Grade 3 or 4
                                                                                      N (%)                              N (%)                                 N (%)                              N (%)
Anemia                                                                                          9 (45.0)                               4 (20.0)                                   8 (44.4)                                3 (16.7)
Thrombocytopenia                                                                    8 (40.0)                               7 (35.0)                                  14 (77.8)                              14 (77.8)
Platelet count decreased                                                     6 (30.0)                               5 (25.0)                                          0                                             0
Pyrexia                                                                                         6 (30.0)                                     0                                          4 (22.2)                                 1 (5.6)
Abdominal pain                                                                          5 (25.0)                                     0                                          4 (22.2)                                      0
Diarrhea                                                                                       5 (25.0)                                1 (5.0)                                    5 (27.8)                                      0
Ecchymosis                                                                                 5 (25.0)                                     0                                          2 (11.1)                                       0
Epistaxis                                                                                      5 (25.0)                                     0                                                0                                             0
White blood cell count decreased                                        5 (25.0)                               2 (10.0)                                    1 (5.6)                                        0
Back pain                                                                                     4 (20.0)                                     0                                          2 (11.1)                                       0
Blood bilirubin increased                                                        4 (20.0)                               2 (10.0)                                    1 (5.6)                                        0
Alanine aminotransferase increased                                  3 (15.0)                                1 (5.0)                                     1 (5.6)                                   1 (5.6)
Aspartate aminotransferase increased                              3 (15.0)                                1 (5.0)                                     1 (5.6)                                        0
Asthenia                                                                                       3 (15.0)                                1 (5.0)                                    5 (27.8)                                2 (11.1)
Fatigue                                                                                          3 (15.0)                                1 (5.0)                                    3 (16.7)                                      0
Neutrophil count decreased                                                   3 (15.0)                                1 (5.0)                                           0                                             0
Cough                                                                                                  0                                             0                                          6 (33.3)                                      0
Hypocalcemia                                                                              2 (10.0)                                      0                                          5 (27.8)                                      0         
Nasopharyngitis                                                                          2 (10.0)                                      0                                          5 (27.8)                                      0         
Headache                                                                                      1 (5.0)                                       0                                          4 (22.2)                                      0
Hypertension                                                                               1 (5.0)                                  1 (5.0)                                     4 (22.2)                                      0
Nausea                                                                                           1 (5.0)                                       0                                          4 (22.2)                                      0
Leukocytosis                                                                                1 (5.0)                                  1 (5.0)                                     3 (16.7)                                 1 (5.6)
Peripheral edema                                                                       1 (5.0)                                  1 (5.0)                                     3 (16.7)                                      0
Pain in extremity                                                                              0                                             0                                          3 (16.7)                                      0
Vomiting                                                                                        1 (5.0)                                       0                                          3 (16.7)                                      0
AE: adverse event; MSSD: maximum safe starting dose.
Figure 3. Mean daily dose over time by 
stratum at  maximum safe starting
dose. bid: twice daily. 
titration in both S1 (n=3) and S2 (n=10). In patients without a dose
down-titration, a decrease in best percentage change from base-
line in spleen length was seen in 94.1% (16 out of 17) of patients
in S1 and 87.5% (7 out of 8) of patients in S2.
Symptom response. An improvement (i.e. decrease) in TSS was
observed at the MSSD in both strata. The mean change in TSS
from baseline at week 24 was –7.7 (SD=9.70) in S1 and –3.9
(SD=11.36) in S2. Compared to the baseline symptom score, the
mean individual symptom scores decreased (improved) for all 
categories except bone/muscle pain (slight worsening) at week 24
(Figure 5). A trend in symptom improvement was also observed in
patients with early dose titration (Online Supplementary Table S9
and Online Supplementary Figure S3).
Discussion
Only a few clinical trials are currently evaluating the
treatment options for patients with MF with thrombocy-
topenia (platelet counts <100x109/L), highlighting the need
for conducting this analysis. The JAK inhibitors that have
been evaluated in this setting include ruxolitinib, pacri-
tinib, momelotinib, and fedratinib;34-36 however, only 
ruxolitinib is currently approved for the treatment of
patients with MF. Ruxolitinib was approved for the treat-
ment of intermediate- and high-risk patients with MF
based on the COMFORT studies in patients with normal
platelet counts (≥100x109/L).9-12,28 Findings from a post hoc
analysis of COMFORT-I  showed that patients with
cytopenias at baseline could be effectively managed with
ruxolitinib dose adjustments and that doses of ≥10 mg bid
yielded clinically meaningful reductions in spleen volume
and symptom improvement.28 These findings support the
use of ruxolitinib as a therapeutic option for patients with
MF with low baseline platelet counts (<100x109/L). 
The preliminary observations based on toxicity during
the first cycle of treatment indicated ruxolitinib 15 mg and
10 mg bid as MSSDs for S1 and S2, respectively. However,
observations from the interim analysis showed that the
majority of patients receiving the 15 mg bid MSSD dose in
S1 experienced thrombocytopenia, thus requiring dose
reductions after the first cycle. These patients 
subsequently continued study treatment at the 10 mg bid
or lower dose. Clinical benefit was observed across all
starting dose levels, including in those patients who start-
ed treatment at the 10 mg bid dose level. Based on these
observations, the initially stated MSSD of 15 mg bid for S1
was revised to 10 mg bid as per protocol amendment.
Based on the results from the interim and 48-week analy-
ses of EXPAND, 10 mg bid was established as the MSSD
for both strata (S1: platelet count=75-99x109/L; S2: platelet
count=50-74x109/L).
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Table 3. New or worsened hematologic abnormalities (week 48 analysis; maximum safe starting dose cohort).
Parameter                                           Worsening from                     Stratum 1 (N=20)                                        Stratum 2 (N=18)
                                                           baseline to the                   Total                          N (%)                     Total                                 N (%)
                                                                following                                                                                                      
Platelets (×109/L)                                              Grade 1                                  2                                       0                                 0                                               0
                                                                               Grade 2                                 15                                5 (25.0)                          1                                          1 (5.6)
                                                                               Grade 3                                 19                                9 (45.0)                         18                                        7 (38.9)
                                                                               Grade 4                                 20                                 1 (5.0)                          18                                        7 (38.9)
Hemoglobin (g/dL)                                            Grade 1                                  5                                 2 (10.0)                          1                                               0
                                                                               Grade 2                                 13                                3 (15.0)                          9                                         6 (33.3)
                                                                               Grade 3                                 18                                5 (25.0)                         12                                         1 (5.6)
                                                                               Grade 4                                 20                                      0                                18                                              0
MSSD: maximum safe starting dose.
Figure 4. Waterfall plot of best response in spleen length by stratum at maximum safe starting dose.
A B
Ruxolitinib was generally well tolerated at all dose 
levels, including the MSSDs, and no new safety signal was
observed. However, as expected, a higher frequency of
thrombocytopenia was observed, which was managed by
dose reduction/interruption. Evidently, the 10 mg bid dose
was better tolerated in S1 versus S2; 3 out of 6 patients in
S1 versus 10 out of 11 patients in S2 did not resume the 
10 mg bid dose after the initial dose reduction (first 12
weeks). A medically meaningful spleen size response was
observed with ruxolitinib treatment at the 10 mg bid dose.
In the MSSD cohort, at least 50% of reduction in the
spleen length was observed in 33.3% of patients in S1 and
30.0% of patients in S2 at week 48, whereas a spleen
response at any time point was achieved by 40.0% of
patients in S1 and 66.7% of patients in S2. A decrease in
the best percentage change from baseline was observed at
the MSSD in 95.0% of patients in S1 and 94.4% of
patients in S2. An improvement in symptom response
(decrease in the MFSAF-TSS) was also observed at the
MSSD in both strata. 
During the first 12 weeks of treatment, the ruxolitinib
dose was reduced below 10 mg bid in some patients,
mostly due to ruxolitinib-associated hematologic toxicity.
However, spleen and symptom benefit was observed in
these patients despite the early dose titration, and the
treatment was continued at the reduced dose, suggesting
that a starting dose of 10 mg bid may still be effective in
the long-term (as was also observed in the COMFORT-I
study).28
In the subgroup with dose down-titration in S1 (3 out of
6 patients), a decrease in the best percentage change from
baseline in spleen length was observed; however, none of
these patients achieved an at least 50% reduction in
spleen length. All patients in S2 (n=10) who had a dose
down-titration achieved a decrease in the best percentage
change from baseline in spleen length; 7 out of 10 patients
achieved an at least 50% reduction in spleen length
(Online Supplementary Figure S2). A trend in symptom
improvement was also observed in patients with early
dose titration at the MSSD; this effect was more pro-
nounced in S1 than in S2 (Online Supplementary Table S9
and Online Supplementary Figure S3). 
The observations from the EXPAND study are consistent
with the findings from other clinical trials evaluating the
use of ruxolitinib in patients with MF with baseline throm-
bocytopenia. In the Study 258, the median percentage
change from baseline in spleen length at week 24 in the 30
evaluable patients was –29.7% (range, –100.0% to 58.3%).
In the EXPAND study, the median percentage change from
baseline in spleen length at week 24 for the overall popula-
tion (n=69) was –36.9% (range, –100.0% to 55.6%). As
expected (owing to baseline patients’ characteristics and the
mechanism of action of ruxolitinib), thrombocytopenia was
frequent in both the Study  258 and the EXPAND study
(64.0% vs. 68.1%, respectively). Low-dose ruxolitinib was
shown to be generally well tolerated and efficacious in
patients with MF with low platelet counts in JUMP.23
The findings to date from the 48-week follow-up 
analysis of the EXPAND study provide evidence to sup-
port a starting dose of ruxolitinib at 10 mg bid for patients
with MF with low baseline platelet counts of 75-99x109/L
(S1) but are less conclusive for baseline platelet counts of
50-74x109/L (S2). The reported AEs were consistent with
the known safety profile of ruxolitinib, with the exception
of thrombocytopenia in S2, which was expected.
Ruxolitinib treatment was generally well tolerated and
provided spleen size reduction and symptom response
benefit. The tolerability of ruxolitinib in this previously
unstudied patient population with MF with low platelet
counts at baseline was acceptable at doses of 10 mg bid in
both strata. The study is ongoing, and further evaluations
will be performed at the end of the study to confirm the
safety and efficacy of ruxolitinib in the study cohorts. 
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Figure 5. Change in total symptom score and individual symptom scores of Myelofibrosis Symptom Assessment Form diary from baseline to week 24 by stratum
at maximum safe starting dose.
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